Radiometals in Imaging and Therapy : Highlighting Two Decades of Research
The present article highlights the important progress made in the last two decades in the fields of molecular imaging and radionuclide therapy. Advancements in radiometal-based positron emission tomography, single photon emission computerized tomography, and radionuclide therapy are illustrated in terms of their production routes and ease of radiolabeling. Applications in clinical diagnostic and radionuclide therapy are considered, including human studies under clinical trials; their current stages of clinical translations and findings are summarized. Because the metalloid astatine is used for imaging and radionuclide therapy, it is included in this review. In regard to radionuclide therapy, both beta-minus (β-) and alpha (α)-emitting radionuclides are discussed by highlighting their production routes, targeted radiopharmaceuticals, and current clinical translation stage.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Pharmaceuticals (Basel, Switzerland) - 16(2023), 10 vom: 13. Okt. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sharma, Shalini [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Imaging |
|---|
| Anmerkungen: |
Date Revised 30.10.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/ph16101460 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363879498 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363879498 | ||
| 003 | DE-627 | ||
| 005 | 20231226094256.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/ph16101460 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1212.xml |
| 035 | |a (DE-627)NLM363879498 | ||
| 035 | |a (NLM)37895931 | ||
| 035 | |a (PII)1460 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sharma, Shalini |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Radiometals in Imaging and Therapy |b Highlighting Two Decades of Research |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 30.10.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a The present article highlights the important progress made in the last two decades in the fields of molecular imaging and radionuclide therapy. Advancements in radiometal-based positron emission tomography, single photon emission computerized tomography, and radionuclide therapy are illustrated in terms of their production routes and ease of radiolabeling. Applications in clinical diagnostic and radionuclide therapy are considered, including human studies under clinical trials; their current stages of clinical translations and findings are summarized. Because the metalloid astatine is used for imaging and radionuclide therapy, it is included in this review. In regard to radionuclide therapy, both beta-minus (β-) and alpha (α)-emitting radionuclides are discussed by highlighting their production routes, targeted radiopharmaceuticals, and current clinical translation stage | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a imaging | |
| 650 | 4 | |a positron emission tomography | |
| 650 | 4 | |a radiometals | |
| 650 | 4 | |a radionuclide therapy | |
| 650 | 4 | |a single photon emission computerized tomography | |
| 700 | 1 | |a Pandey, Mukesh K |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmaceuticals (Basel, Switzerland) |d 2009 |g 16(2023), 10 vom: 13. Okt. |w (DE-627)NLM199619514 |x 1424-8247 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2023 |g number:10 |g day:13 |g month:10 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/ph16101460 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2023 |e 10 |b 13 |c 10 | ||